Equities analysts expect Menlo Therapeutics Inc (NASDAQ:MNLO) to report ($0.83) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Menlo Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.85) and the highest estimate coming in at ($0.81). Menlo Therapeutics reported earnings of ($0.76) per share during the same quarter last year, which would indicate a negative year over year growth rate of 9.2%. The business is expected to issue its next earnings report on Wednesday, February 26th.
On average, analysts expect that Menlo Therapeutics will report full year earnings of ($3.08) per share for the current fiscal year, with EPS estimates ranging from ($3.15) to ($3.01). For the next year, analysts expect that the firm will post earnings of ($2.54) per share, with EPS estimates ranging from ($3.09) to ($1.88). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Menlo Therapeutics.
Menlo Therapeutics (NASDAQ:MNLO) last released its earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.07.
Shares of Menlo Therapeutics stock traded up $0.13 during trading on Thursday, hitting $4.11. The stock had a trading volume of 45,300 shares, compared to its average volume of 66,467. The stock has a 50 day simple moving average of $4.77 and a 200 day simple moving average of $5.18. The company has a market capitalization of $104.57 million, a PE ratio of -1.73 and a beta of 2.19. Menlo Therapeutics has a 1 year low of $2.69 and a 1 year high of $9.03.
Several hedge funds have recently bought and sold shares of the stock. BlackRock Inc. boosted its holdings in shares of Menlo Therapeutics by 44.7% during the second quarter. BlackRock Inc. now owns 912,720 shares of the company’s stock worth $5,466,000 after purchasing an additional 281,974 shares during the period. Orbimed Advisors LLC boosted its holdings in shares of Menlo Therapeutics by 6.3% during the second quarter. Orbimed Advisors LLC now owns 673,700 shares of the company’s stock worth $4,035,000 after purchasing an additional 39,780 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Menlo Therapeutics by 4.3% during the second quarter. Vanguard Group Inc. now owns 559,499 shares of the company’s stock worth $3,352,000 after purchasing an additional 22,996 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Menlo Therapeutics by 8.8% during the second quarter. Jacobs Levy Equity Management Inc. now owns 114,109 shares of the company’s stock worth $684,000 after purchasing an additional 9,216 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in shares of Menlo Therapeutics by 131.6% during the second quarter. Renaissance Technologies LLC now owns 110,000 shares of the company’s stock worth $659,000 after purchasing an additional 62,500 shares during the period. Institutional investors and hedge funds own 76.13% of the company’s stock.
About Menlo Therapeutics
Menlo Therapeutics Inc, a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough.
Featured Article: How to find the components of the quick ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.